d-alpha tocopherol has been researched along with triclabendazole in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| el-Toukhy, MA; Fouad, HN; Hishmat, M; Rawash, NA; Rehim, WM; Sharaf, IA | 1 |
| Daware, S; Palekar, S; Patel, K; Patki, M; Saraswat, A | 1 |
1 trial(s) available for d-alpha tocopherol and triclabendazole
| Article | Year |
|---|---|
Antioxidant capacity in Fasciola hepatica patients before and after treatment with triclabendazole alone or in combination with ascorbic acid (vitamin C) and tocofersolan (vitamin E).
Topics: Acute Disease; Adolescent; Adult; Anthelmintics; Antioxidants; Ascorbic Acid; Benzimidazoles; Chronic Disease; Drug Combinations; Erythrocytes; Fascioliasis; Female; Glutathione; Glutathione Peroxidase; Humans; Lipid Peroxides; Liver Function Tests; Male; Superoxide Dismutase; Triclabendazole; Vitamin E | 2003 |
1 other study(ies) available for d-alpha tocopherol and triclabendazole
| Article | Year |
|---|---|
Development of a safe pediatric liquisolid self-nanoemulsifying system of triclabendazole for the treatment of fascioliasis.
Topics: alpha-Tocopherol; Biological Availability; Child; Drug Delivery Systems; Emulsions; Fascioliasis; Humans; Lipids; Nanoparticles; Particle Size; Solubility; Solvents; Surface-Active Agents; Tablets; Triclabendazole; Triglycerides | 2022 |